Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 2/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851363 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL23480038 | 0.89 | HSD11B1 (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL29851378 | 0.89 | HSD11B1 (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL25047487 | 0.89 | HSD11B1 (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL29170993 | 0.89 | HSD11B1 (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL25047183 | 0.82 | SIRT6 (0.56) | ALDH1A1LMNASIRT6MAPTMAPK1 | |
| SCHEMBL24658841 | 0.82 | LMNA (0.47) | ALDH1A1LMNASIRT6MAPTSMN1; SMN2 | |
| SCHEMBL29851330 | 0.81 | SIGMAR1 (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1SIGMAR1 | |
| SCHEMBL23479987 | 0.81 | SIGMAR1 (0.42) | CYP3A4CYP2C9CYP2C19ALDH1A1SIGMAR1 | |
| SCHEMBL23479973 | 0.81 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4074697-B1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | SAMJIN PHARM CO LTD (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-114929675-B | Adamantane derivatives as focal adhesion kinase inhibitors | 三进制药株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
| EP-4074697-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | Samjin Pharmaceutical Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074697-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | Samjin Pharmaceutical Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114929675-A | Novel adamantane derivatives as inhibitors of focal adhesion kinase | 三进制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021111311-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | 삼진제약주식회사 | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | PTK2, DAPK2, DAPK1 | CYP3A4 4501/4885CYP2C9 4559/4885CYP2C19 4338/4885 |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | PTK2, CTTN, ADGRF1 | CYP3A4 4664/4885CYP2C9 4413/4885CYP2C19 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.